Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.

Jun MaShoujing ZhaoXinan QiaoTristan E KnightHolly EdwardsLisa PolinJuiwanna KushnerSijana H DzinicKathryn WhiteGuan WangLijing ZhaoHai LinYue WangJeffrey W TaubYubin Ge

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

Inhibition of Bcl-2 via venetoclax synergistically enhances the efficacy of midostaurin and gilteritinib in FLT3-mutated AML.See related commentary by Perl, p. 6567.

Keyphrases

acute myeloid leukemia
allogeneic hematopoietic stem cell transplantation
stem cells
acute lymphoblastic leukemia
bone marrow
mesenchymal stem cells
drug induced